Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F14%3A43908429" target="_blank" >RIV/00216208:11120/14:43908429 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1586/17434440.2014.900434" target="_blank" >http://dx.doi.org/10.1586/17434440.2014.900434</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1586/17434440.2014.900434" target="_blank" >10.1586/17434440.2014.900434</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease

Popis výsledku v původním jazyce

Drug eluting stents were an important addition to the interventional options available for patients with coronary artery disease, and they effectively reduced the risk of restenosis observed with bare metal stents. However, the drugs and polymers used inthe composition of drug eluting stents were found to delay vascular healing and elicit inflammatory responses, which contributed to late and very late stent thrombosis events. Newer generation drug eluting stents have been engineered with polymers thatare more biocompatible and have more favorable drug elution profiles. The Resolute(?) zotarolimus eluting stent (R-ZES) is a new-generation drug eluting stent. The Global RESOLUTE clinical program was designed to evaluate the safety and efficacy of the R-ZES. The studies conducted under this program have established that the R-ZES safely and effectively treats coronary artery stenosis, with low rates of target lesion failure, target vessel revascularization, and stent thrombosis during e

Název v anglickém jazyce

Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease

Popis výsledku anglicky

Drug eluting stents were an important addition to the interventional options available for patients with coronary artery disease, and they effectively reduced the risk of restenosis observed with bare metal stents. However, the drugs and polymers used inthe composition of drug eluting stents were found to delay vascular healing and elicit inflammatory responses, which contributed to late and very late stent thrombosis events. Newer generation drug eluting stents have been engineered with polymers thatare more biocompatible and have more favorable drug elution profiles. The Resolute(?) zotarolimus eluting stent (R-ZES) is a new-generation drug eluting stent. The Global RESOLUTE clinical program was designed to evaluate the safety and efficacy of the R-ZES. The studies conducted under this program have established that the R-ZES safely and effectively treats coronary artery stenosis, with low rates of target lesion failure, target vessel revascularization, and stent thrombosis during e

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Medical Devices

ISSN

1743-4440

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

247-257

Kód UT WoS článku

000337493400002

EID výsledku v databázi Scopus

—